OnKure Therapeutics (OKUR)
NASDAQ:OKUR
OKUR Stock Chart & Stats
$4.00
-$0.05(-0.63%)
At close: 4:00 PM EST
$4.00
-$0.05(-0.63%)
Day’s Range― - ―
52-Week Range$1.70 - $4.90
Previous CloseN/A
Volume8.61K
Average Volume (3M)86.56K
Market Cap
$62.76M
Enterprise Value$4.26M
Total Cash (Recent Filing)$59.05M
Total Debt (Recent Filing)$549.00K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
May 12, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding13,673,565
10 Day Avg. Volume131,167
30 Day Avg. Volume86,556
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.09
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$23.75Price Target Upside493.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.73
Revenue Forecast (FY)$666.67K
Bulls Say, Bears Say
Bulls Say
Clinical Data ClarityAnalyst notes the PIKture-01 clinical update could clarify OKI-219's efficacy and safety across monotherapy and combination arms, giving investors a clearer view of the lead program's expected clinical profile.
Pipeline DiversificationAnalyst points out selection of a pan-PI3Kα mutant-selective molecule and expansion into PI3KCA-driven vascular malformations, which could diversify commercial opportunities beyond the lead oncology program.
Triplet Combination ProgressAnalyst highlights initiation and dosing in triplet therapy arms combining OKI-219 with endocrine and HER2-targeted agents, which could broaden treatment indications and support a move into earlier-line breast cancer if tolerability and early efficacy are favorable.
Bears Say
Competitive Benchmark RiskAnalyst cautions that strong benchmark results from competitors raise the bar for the company's doublet combination, making patient mix and trial comparability critical to assess competitiveness.
Funding And Cash Runway PressureAnalyst warns high cash burn and modest available cash create funding pressure and increase the likelihood of additional financing needs to sustain ongoing development activities.
Incomplete Efficacy EndpointsAnalyst warns that progression-free survival may not be available for every treatment arm and reported durability alone could limit the ability to draw definitive efficacy conclusions.
OnKure Therapeutics News
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $1.70 and its highest was $4.90 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $62.76M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 45 days.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.99 earnings per share for the quarter, beating the consensus estimate of -$1.152 by $0.162.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate is -0.86.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 13,673,565 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$0.99 in its last earnings report, beating expectations of -$1.152. Following the earnings report the stock price went up 7.386%.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OnKure Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.75 (493.75% Upside)
$23.75 (493.75% Upside)
Hedge Fund Trend
Decreased
By 107.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 12.7%
Last 30 Days ▲ 12.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.51%
12-Months-Change
Fundamentals
Return on Equity
-115.64%
Trailing 12-Months
Asset Growth
9.34%
Trailing 12-Months
Company Description
OnKure Therapeutics
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
OKUR Stock 12 Month Forecast
Average Price Target
$23.75
▲(493.75% Upside)